Targeting microRNA‐485‐3p blocks Alzheimer's disease progression

Abstract

AbstractBackgroundAlzheimer’s disease (AD) is a form of dementia characterized by progressive memory decline and cognitive dysfunction, which affects more than 44 million people worldwide. Currently, there is no effective therapy for AD despite its increasing global incidence; thus, effective treatment strategies for AD are urgently needed. While several drugs that decrease amyloid beta (Aβ) production or increase Aβ clearance in the brain have been identified, treatment with these drugs is poorly correlated with improvements in AD severity and cognitive dysfunction.MethodExpression of miR‐485‐3p was analysed by real‐time PCR in the human frontal cortex (8 healthy controls (HC), 7 AD patients), precentral gyrus (6 HC, 8 AD), cerebrospinal fluid (CSF) (6 HC, 7 AD), plasma exosomes (10 HC, 17 mild cognitive impairment (MCI), 12 AD). Aβ 1–42 plaque immunofluorescence and tau pathology were imaged in primary cultured mouse neurons after lentivirus‐derived miR485‐3p transduction. MiR‐485‐3p antisense oligonucleotide (ASO, 1.5 μg) or control oligonucleotide formulated with the in vivo jetPEI reagent was injected into 8‐month‐old 5XFAD mice by ICV injection once weekly for two weeks. Behavioral tests were performed at 8 months and their brain pathology was examined after 8‐week‐washout at 10 months.ResultWe found that the miR‐485‐3p is overexpressed in brain tissues and CSF of AD patients, and its ASO reduces Aβ plaques, tau pathology, neuroinflammation, and cognitive decline in a transgenic mouse model of AD. Mechanistically, miR‐485‐3p ASO enhanced Aβ clearance via CD36‐mediated phagocytosis of Aβ in vitro and in vivo. We found that miR‐485‐3p ASO reduces apoptosis, which effectively decreases truncated tau levels. Further, miR‐485‐3p ASO reduced secretion of pro‐inflammatory cytokines, including IL‐1β and TNF‐α, and eventually relieved cognitive impairment.ConclusionCollectively, our findings suggest that miR‐485‐3p is a useful biomarker as well as a causative factor of the inflammatory pathophysiology of AD; furthermore, miR‐485‐3p ASO represents a candidate therapy for AD pathology and cognitive decline, establishing a new paradigm in the AD field.